Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fibrosis – Pipeline Review, H1 2017, provides an overview of the Fibrosis (Musculoskeletal Disorders) pipeline landscape.
Fibrosis is the excessive formation of fibrous bands of scar tissue in between muscle fibers. Fibrous scar tissue develops after the muscle has been damaged to fill in the open spaces in the injured muscle, providing more surface area for the regenerating muscle fibers to adhere to. The connective tissue cells that comprise scar tissue are unable to contract and relax to enable movement. The abnormal development of fibrosis causes muscle weakness, fatigue, and an inability to perform activities. Treatment includes anti-fibrosis agents and surgery.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fibrosis – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Fibrosis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Fibrosis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 5, 30 and 17 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.
Fibrosis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Fibrosis (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Fibrosis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Fibrosis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Fibrosis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Fibrosis (Musculoskeletal Disorders)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Fibrosis (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Fibrosis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Acceleron Pharma Inc
Aelis Farma SAS
Allakos Inc
Anima Biotech Ltd
Bristol-Myers Squibb Company
Calypso Biotech SA
Complexa Inc
Encycle Therapeutics Inc
F. Hoffmann-La Roche Ltd
Five Prime Therapeutics Inc
Genfit SA
GlycoMimetics Inc
Hanmi Pharmaceuticals Co Ltd
iBio Inc
Immunomet Therapeutics Inc
Inception Sciences Inc
Insmed Inc
Inventiva
Ironwood Pharmaceuticals Inc
Isarna Therapeutics GmbH
Lycera Corp
Neumedicines Inc
Novartis AG
Palatin Technologies Inc
Ribomic Inc
Scholar Rock Inc
SciFluor Life Sciences LLC
SK Chemicals Co Ltd
UCB SA
VivaCell Biotechnology Espana SL
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Fibrosis – Overview 8
Fibrosis – Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 14
Products under Development by Companies 15
Products under Development by Universities/Institutes 18
Fibrosis – Therapeutics Assessment 19
Assessment by Target 19
Assessment by Mechanism of Action 22
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Fibrosis – Companies Involved in Therapeutics Development 29
Acceleron Pharma Inc 29
Aelis Farma SAS 29
Allakos Inc 30
Anima Biotech Ltd 30
Bristol-Myers Squibb Company 31
Calypso Biotech SA 31
Complexa Inc 32
Encycle Therapeutics Inc 32
F. Hoffmann-La Roche Ltd 33
Five Prime Therapeutics Inc 33
Genfit SA 34
GlycoMimetics Inc 34
Hanmi Pharmaceuticals Co Ltd 35
iBio Inc 35
Immunomet Therapeutics Inc 36
Inception Sciences Inc 36
Insmed Inc 37
Inventiva 37
Ironwood Pharmaceuticals Inc 38
Isarna Therapeutics GmbH 38
Lycera Corp 39
Neumedicines Inc 39
Novartis AG 40
Palatin Technologies Inc 40
Ribomic Inc 41
Scholar Rock Inc 41
SciFluor Life Sciences LLC 42
SK Chemicals Co Ltd 42
UCB SA 43
VivaCell Biotechnology Espana SL 43
Fibrosis – Drug Profiles 44
ACE-2798 – Drug Profile 44
AEF-0118 – Drug Profile 45
AK-002 – Drug Profile 46
Antibody to Inhibit Transglutaminase 2 for Fibrosis – Drug Profile 48
CALY-001 – Drug Profile 49
CWHM-12 – Drug Profile 50
elafibranor – Drug Profile 51
G-XXX – Drug Profile 60
IB-DMD – Drug Profile 61
IBIOCFB-03 – Drug Profile 62
IM-156 – Drug Profile 64
INS-1007 – Drug Profile 65
ISTH-1106 – Drug Profile 66
IW-1701 – Drug Profile 67
IW-1973 – Drug Profile 68
LYC-53976 – Drug Profile 70
Monoclonal Antibodies for Fibrosis – Drug Profile 71
Monoclonal Antibodies to Inhibit TGF Beta 1 for Fibrosis – Drug Profile 72
Monoclonal Antibody 2 for Fibrosis – Drug Profile 73
Monoclonal Antibody for Fibrotic Scar – Drug Profile 74
Monoclonal Antibody to Activate BMP7 for Fibrosis – Drug Profile 75
NCE-401 – Drug Profile 76
Neumomir – Drug Profile 77
NMIL-121 – Drug Profile 78
OCX-063 – Drug Profile 82
PAT-048 – Drug Profile 83
PL-5028 – Drug Profile 84
PRI-724 – Drug Profile 85
Proteins for Central Nervous System Disorders and Fibrosis – Drug Profile 87
RBM-003 – Drug Profile 88
RBM-007 – Drug Profile 89
Recombinant Protein 1 to Agonize Fibroblast Growth Factor Receptor for Fibrosis – Drug Profile 90
Recombinant Protein to Antagonize TGF beta for Immunology, Dermatology, Gastrointestinal and Musculoskeletal Disorders – Drug Profile 91
RG-6125 – Drug Profile 92
Small Molecule for Fibrosis – Drug Profile 94
Small Molecule for Fibrosis – Drug Profile 95
Small Molecule to Inhibit Galectin-3 for Fibrosis, Oncology and Cardiovascular Disease – Drug Profile 96
Small Molecule to Inhibit LOXL2 for Fibrosis – Drug Profile 97
Small Molecule to Inhibit MicroRNA for Vascular Fibrosis – Drug Profile 98
Small Molecules for Fibrosis – Drug Profile 99
Small Molecules for Fibrosis – Drug Profile 100
Small Molecules for Fibrosis – Drug Profile 101
Small Molecules for Fibrosis – Drug Profile 102
Small Molecules for Fibrosis – Drug Profile 103
Small Molecules for Fibrosis – Drug Profile 104
Small Molecules for Fibrosis and Inflammatory Diseases – Drug Profile 105
Small Molecules for Fibrosis and Oncology – Drug Profile 106
Small Molecules to Activate RXFP1 for Heart Failure and Fibrosis – Drug Profile 107
Small Molecules to Antagonize Integrin Alpha V for Fibrosis – Drug Profile 108
Small Molecules to Inhibit Galectin-9 for Fibrosis, Oncology and Cardiovascular Disease – Drug Profile 109
Small Molecules to Inhibit SMURF2 for Fibrosis and Oncology – Drug Profile 110
Small Molecules to Inhibit SphK1 for Autoimmune Disorders, Fibrosis, Neurodegenerative Diseases and Oncology – Drug Profile 111
SRI-31277 – Drug Profile 112
ST-2001 – Drug Profile 113
Synthetic Peptides to Inhibit TGFb for Fibrosis and Oncology – Drug Profile 114
VCE-0048 – Drug Profile 115
X-165 – Drug Profile 116
XOMA-089 – Drug Profile 117
Fibrosis – Dormant Projects 118
Fibrosis – Product Development Milestones 120
Featured News & Press Releases 120
Appendix 127
Methodology 127
Coverage 127
Secondary Research 127
Primary Research 127
Expert Panel Validation 127
Contact Us 127
Disclaimer 128
List of Tables
Number of Products under Development for Fibrosis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Fibrosis – Pipeline by Acceleron Pharma Inc, H1 2017
Fibrosis – Pipeline by Aelis Farma SAS, H1 2017
Fibrosis – Pipeline by Allakos Inc, H1 2017
Fibrosis – Pipeline by Anima Biotech Ltd, H1 2017
Fibrosis – Pipeline by Bristol-Myers Squibb Company, H1 2017
Fibrosis – Pipeline by Calypso Biotech SA, H1 2017
Fibrosis – Pipeline by Complexa Inc, H1 2017
Fibrosis – Pipeline by Encycle Therapeutics Inc, H1 2017
Fibrosis – Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Fibrosis – Pipeline by Five Prime Therapeutics Inc, H1 2017
Fibrosis – Pipeline by Genfit SA, H1 2017
Fibrosis – Pipeline by GlycoMimetics Inc, H1 2017
Fibrosis – Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
Fibrosis – Pipeline by iBio Inc, H1 2017
Fibrosis – Pipeline by Immunomet Therapeutics Inc, H1 2017
Fibrosis – Pipeline by Inception Sciences Inc, H1 2017
Fibrosis – Pipeline by Insmed Inc, H1 2017
Fibrosis – Pipeline by Inventiva, H1 2017
Fibrosis – Pipeline by Ironwood Pharmaceuticals Inc, H1 2017
Fibrosis – Pipeline by Isarna Therapeutics GmbH, H1 2017
Fibrosis – Pipeline by Lycera Corp, H1 2017
Fibrosis – Pipeline by Neumedicines Inc, H1 2017
Fibrosis – Pipeline by Novartis AG, H1 2017
Fibrosis – Pipeline by Palatin Technologies Inc, H1 2017
Fibrosis – Pipeline by Ribomic Inc, H1 2017
Fibrosis – Pipeline by Scholar Rock Inc, H1 2017
Fibrosis – Pipeline by SciFluor Life Sciences LLC, H1 2017
Fibrosis – Pipeline by SK Chemicals Co Ltd, H1 2017
Fibrosis – Pipeline by UCB SA, H1 2017
Fibrosis – Pipeline by VivaCell Biotechnology Espana SL, H1 2017
Fibrosis – Dormant Projects, H1 2017
Fibrosis – Dormant Projects, H1 2017 (Contd..1), H1 2017
List of Figures
Number of Products under Development for Fibrosis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017
